Recall Record

Windsor, CT, United States

SCA Pharmaceuticals recalls

18 recalls recorded since 2018, most recently on 9 November 2023. None are listed as ongoing. Status and classification are as published by the FDA.

Recalls18
Ongoing (FDA)0
Terminated or completed18
Class I (FDA)2

Terminated Class II Drugs

Recall started
9 November 2023
Terminated
27 August 2024
Reason
Lack of Assurance of Sterility
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0417-2024, D-0411-2024, D-0410-2024, D-0419-2024, D-0399-2024, D-0402-2024, D-0407-2024, D-0418-2024, D-0424-2024, D-0395-2024, D-0403-2024, D-0413-2024 and 20 more

Terminated Class II Drugs

Recall started
20 July 2023
Terminated
21 September 2023
Reason
cGMP deviations: due to shipment of rejected units.
Distribution
KY and NJ
Initiated
Voluntary: Firm initiated
Recall number
D-0945-2023

Terminated Class III Drugs

Recall started
10 April 2023
Terminated
20 September 2023
Reason
Subpotent Drug: Out of specification results for low potency was obtained.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0555-2023

Terminated Class III Drugs

Recall started
24 February 2023
Terminated
21 June 2023
Reason
Subpotent Drug
Distribution
Nationwide in the US.
Initiated
Voluntary: Firm initiated
Recall number
D-0363-2023

Terminated Class II Drugs

Recall started
25 April 2022
Terminated
9 September 2022
Reason
CGMP Deviations
Distribution
Product was distributed nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall numbers
D-0831-2022, D-0829-2022, D-0830-2022

Terminated Class II, Class III Drugs

Recall started
17 December 2020
Terminated
2 November 2021
Reason
Lack of Assurance of Sterility; potential for a defective syringe cap, resulting in a non-integral unit
Distribution
Product was distributed to hospitals nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0215-2021, D-0189-2021, D-0216-2021, D-0213-2021, D-0191-2021, D-0207-2021, D-0202-2021, D-0188-2021, D-0190-2021, D-0194-2021, D-0214-2021, D-0186-2021 and 20 more

Terminated Class II Drugs

Recall started
14 December 2020
Terminated
23 September 2021
Reason
Subpotent drug.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0171-2021

Terminated Class III Drugs

Recall started
20 November 2020
Terminated
24 June 2021
Reason
Subpotency: Out-of-specification stability test result for low potency was obtained.
Distribution
Product was distributed to three hospitals in MO & LA.
Initiated
Voluntary: Firm initiated
Recall number
D-0147-2021

Terminated Class I Drugs

Recall started
29 July 2020
Terminated
21 May 2021
Reason
Cross Contamination with Other Product(s): containers labeled as having methylparaben and propylparaben as preservatives, actually contained undeclared benzyl alcohol and did not contain any parabens.
Distribution
Nationwide within the U.S.
Initiated
Voluntary: Firm initiated
Recall numbers
D-1553-2020, D-1550-2020, D-1552-2020, D-1551-2020

Terminated Class II Drugs

Recall started
29 July 2020
Terminated
17 March 2021
Reason
Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint.
Distribution
Product was distributed nationwide within the United States.
Initiated
Voluntary: Firm initiated
Recall number
D-1495-2020

Terminated Class II Drugs

Recall started
16 June 2020
Terminated
17 March 2021
Reason
Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint.
Distribution
Product was distributed to hospitals in PA and CA.
Initiated
Voluntary: Firm initiated
Recall number
D-1311-2020

Terminated Class II Drugs

Recall started
26 November 2019
Terminated
7 February 2020
Reason
Presence of Foreign Substance: Foreign material found inside the vial (manufacturer).
Distribution
nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0620-2020

Terminated Class II Drugs

Recall started
16 August 2019
Terminated
15 October 2019
Reason
Lack of Assurance of Sterility.
Distribution
Nationwide in the U.S.
Initiated
Voluntary: Firm initiated
Recall number
D-1843-2019

Terminated Class I Drugs

Recall started
27 August 2018
Terminated
2 June 2020
Reason
Presence of Precipitate: Customer complaint for visible precipitate in product believed to be the active ingredient furosemide.
Distribution
Three hospitals in DC, VA, CT
Initiated
Voluntary: Firm initiated
Recall number
D-1189-2018

Terminated Class II Drugs

Recall started
29 June 2018
Terminated
1 May 2019
Reason
Subpotent Drug: Stability data does not support the current expiration dating of 55 days after compounding.
Distribution
United States
Initiated
Voluntary: Firm initiated
Recall number
D-0918-2018

Terminated Class II Drugs

Recall started
14 June 2018
Terminated
4 February 2019
Reason
Lack of Assurance of Sterility: SCA is conducting a voluntary recall of certain lots of sterile admixtures due to a potential for leakage.
Distribution
Product was distributed throughout the United States.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0899-2018, D-0897-2018, D-0901-2018, D-0903-2018, D-0894-2018, D-0895-2018, D-0898-2018, D-0900-2018, D-0904-2018, D-0896-2018, D-0902-2018, D-0905-2018

Terminated Class III Drugs

Recall started
22 February 2018
Terminated
26 February 2019
Reason
Labeling; Incorrect or Missing Lot number/Expiration Date; some product labels incorrectly indicates a compounding date of 12/27/2018 and use-by date of 03/27/2019 instead of 12/27/2017 and use-by-date of 03/27/2018
Distribution
GA, NE & PA
Initiated
Voluntary: Firm initiated
Recall number
D-0603-2018

Terminated Class II Drugs

Recall started
7 December 2017
Terminated
1 May 2019
Reason
Labeling: Incorrect or Missing Lot and/or Exp Date - product label was missing lot number and beyond use date.
Distribution
U.S.A. Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0156-2018

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.